Adc Therapeutics Sa Stock Performance
| ADCT Stock | USD 2.26 0.04 1.80% |
The firm owns a Beta (Systematic Risk) of 2.4, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ADC Therapeutics will likely underperform. At this point, ADC Therapeutics has a negative expected return of -0.29%. Please make sure to confirm ADC Therapeutics' information ratio, as well as the relationship between the potential upside and rate of daily change , to decide if ADC Therapeutics performance from the past will be repeated at some future date.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days ADC Therapeutics SA has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 1.58 | Five Day Return 17.45 | Year To Date Return 33.43 | Ten Year Return (92.39) | All Time Return (92.39) |
1 | 474,744 Shares in ADC Therapeutics SA Purchased by Affinity Asset Advisors LLC - MarketBeat | 09/25/2024 |
2 | Antibody Drug Conjugates Industry Report Featuring Profiles the Top 13 Players - ADC Therapeutics, Astellas Pharma, AstraZeneca, Celldex Therapeutics, Roche Mor... | 10/09/2024 |
3 | ADC Therapeutics Set to Announce Earnings on Thursday | 11/01/2024 |
4 | ADC Therapeutics to Present at November Investor Conferences | 11/04/2024 |
5 | What To Expect From ADC Therapeutics SA Q3 2024 Earnings | 11/06/2024 |
6 | ADC Therapeutics SA Reports Q3 2024 EPS of -0.42 Misses Estimates, Revenue at 18. ... | 11/07/2024 |
7 | ADC Therapeutics SA Q3 2024 Earnings Call Transcript | 11/11/2024 |
8 | Redmile Group, LLC Reduces Stake in ADC Therapeutics SA | 11/15/2024 |
9 | ADC Therapeutics SA Reports Q3 Loss, Lags Revenue Estimates - MSN | 11/20/2024 |
| Begin Period Cash Flow | 326.4 M |
ADC |
ADC Therapeutics Relative Risk vs. Return Landscape
If you would invest 290.00 in ADC Therapeutics SA on August 30, 2024 and sell it today you would lose (64.00) from holding ADC Therapeutics SA or give up 22.07% of portfolio value over 90 days. ADC Therapeutics SA is currently does not generate positive expected returns and assumes 4.5152% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than ADC, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ADC Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ADC Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ADC Therapeutics SA, and traders can use it to determine the average amount a ADC Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0652
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ADCT |
Estimated Market Risk
| 4.52 actual daily | 40 60% of assets are more volatile |
Expected Return
| -0.29 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average ADC Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ADC Therapeutics by adding ADC Therapeutics to a well-diversified portfolio.
ADC Therapeutics Fundamentals Growth
ADC Stock prices reflect investors' perceptions of the future prospects and financial health of ADC Therapeutics, and ADC Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ADC Stock performance.
| Return On Equity | -7.06 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (3.00) % | ||||
| Operating Margin | (1.93) % | ||||
| Current Valuation | 64.93 M | ||||
| Shares Outstanding | 96.69 M | ||||
| Price To Earning | 19.80 X | ||||
| Price To Book | 2.58 X | ||||
| Price To Sales | 3.04 X | ||||
| Revenue | 69.56 M | ||||
| Gross Profit | 35.1 M | ||||
| EBITDA | (146.76 M) | ||||
| Net Income | (240.05 M) | ||||
| Cash And Equivalents | 376.78 M | ||||
| Cash Per Share | 4.90 X | ||||
| Total Debt | 124.38 M | ||||
| Debt To Equity | 2.75 % | ||||
| Current Ratio | 5.76 X | ||||
| Book Value Per Share | (1.78) X | ||||
| Cash Flow From Operations | (118.69 M) | ||||
| Earnings Per Share | (2.39) X | ||||
| Market Capitalization | 214.65 M | ||||
| Total Asset | 354.78 M | ||||
| Retained Earnings | (1.34 B) | ||||
| Working Capital | 268.62 M | ||||
| Current Asset | 1.11 B | ||||
| Current Liabilities | 288.7 M | ||||
About ADC Therapeutics Performance
Assessing ADC Therapeutics' fundamental ratios provides investors with valuable insights into ADC Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the ADC Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 2.3 K | 2.5 K | |
| Return On Tangible Assets | (0.68) | (0.71) | |
| Return On Capital Employed | (0.58) | (0.61) | |
| Return On Assets | (0.68) | (0.71) | |
| Return On Equity | 1.62 | 1.70 |
Things to note about ADC Therapeutics performance evaluation
Checking the ongoing alerts about ADC Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ADC Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ADC Therapeutics generated a negative expected return over the last 90 days | |
| ADC Therapeutics has high historical volatility and very poor performance | |
| ADC Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 69.56 M. Net Loss for the year was (240.05 M) with profit before overhead, payroll, taxes, and interest of 35.1 M. | |
| ADC Therapeutics SA currently holds about 376.78 M in cash with (118.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 62.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: ADC Therapeutics SA Reports Q3 Loss, Lags Revenue Estimates - MSN |
- Analyzing ADC Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ADC Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining ADC Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ADC Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ADC Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ADC Therapeutics' stock. These opinions can provide insight into ADC Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.